THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 1993 Session of 2024

INTRODUCED BY BENHAM, GAYDOS, KENYATTA, BURGOS, HARKINS, DONAHUE, MADDEN, MAJOR, SANCHEZ, CERRATO, HILL-EVANS, D'ORSIE, CIRESI, GREEN, DALEY, MATZIE, SOLOMON, MIHALEK, ECKER, McNEILL, SCHLOSSBERG, PICKETT, PISCIOTTANO, WEBSTER, HOHENSTEIN, KRUEGER, BOROWSKI, NEILSON, FEE, KIM, KHAN, BERNSTINE, MENTZER, O'MARA, FLEMING, GROVE, MULLINS, KOSIEROWSKI, ISAACSON, HEFFLEY, OBERLANDER, ARMANINI, GREGORY, E. NELSON, STAATS, WAXMAN, STEELE, SALISBURY, KINKEAD, McANDREW, KAUFFMAN, GIRAL, DELOZIER, FRITZ, MUSTELLO, POWELL, D. WILLIAMS, HOGAN, CAUSER, FRIEL, SIEGEL, WARNER, COOPER, SAMUELSON, KRAJEWSKI, SHUSTERMAN, FRANKEL, KRUPA, MADSEN, ABNEY, BRIGGS AND HANBIDGE, APRIL 3, 2024

AS AMENDED ON SECOND CONSIDERATION, HOUSE OF REPRESENTATIVES, JUNE 27, 2024

AN ACT

- Amending the act of November 21, 2016 (P.L.1318, No.169), entitled "An act providing for pharmacy audit procedures, for 2 registration of pharmacy benefits managers and auditing 3 entities, for maximum allowable cost transparency and for prescription drugs reimbursed under the PACE and PACENET 5 program; and making related repeals," further providing for title of act; in preliminary provisions, further providing 7 for short title and for definitions; in pharmacy audits, further providing for limitations; in registration, further 9 providing for PBM and auditing entity registration; providing 10 for pharmacy benefits manager contract requirements and 11 12 prohibited acts; in PBM cost transparency requirements, providing for transparency report required; and, in 13 enforcements, further providing for scope of enforcement authority and providing for regulations and for construction. 15 16 The General Assembly of the Commonwealth of Pennsylvania
- 17 hereby enacts as follows:
- 18 Section 1. The title and section 101 of the act of November
- 19 21, 2016 (P.L.1318, No.169), known as the Pharmacy Audit

- 1 Integrity and Transparency Act, are amended to read:
- 2 AN ACT
- 3 Providing for pharmacy audit procedures, for registration
- 4 ofpharmacy benefits managers and auditing entities, for
- 5 maximum allowable cost transparency and for prescription
- drugs reimbursed under the PACE and PACENET program and for
- 7 pharmacy benefit managers contract requirements and
- 8 prohibited activities; and making related repeals.
- 9 Section 101. Short title.
- 10 This act shall be known and may be cited as the [Pharmacy
- 11 Audit Integrity and Transparency] Pharmacy Benefit Reform Act.
- 12 Section 2. The definitions of "covered entity" and "health
- 13 insurance policy" in section 103 of the act are amended and the
- 14 section is amended by adding definitions to read:
- 15 Section 103. Definitions.
- 16 The following words and phrases when used in this act shall
- 17 have the meanings given to them in this section unless the
- 18 context clearly indicates otherwise:
- 19 * * *
- 20 "Brand effective rate." The reimbursement rate paid to the
- 21 pharmacy based on a percentage of the average wholesale cost for
- 22 <u>brand-name drugs dispensed by the pharmacy under the contract</u>
- 23 with the pharmacy benefit manager.
- 24 * * *
- 25 "Covered entity." A contract holder or policy holder
- 26 providing pharmacy benefits to a covered individual under a
- 27 health [insurance policy] benefit plan pursuant to a contract
- 28 administered by a pharmacy benefit manager.
- 29 * * *
- 30 <u>"Effective rate contract." A contract that sets a specific</u>

- 1 discount rate for all prescriptions filled by a member pharmacy
- 2 during the term of the contract.
- 3 * * *
- 4 <u>"Generic effective rate."</u> The reimbursement rate paid to the
- 5 pharmacy based on a percentage of the average wholesale cost for
- 6 generic drugs dispensed by the pharmacy under the contract with
- 7 the pharmacy benefit manager.
- 8 * * *
- 9 "Health benefit plan." A policy, contract, certificate or
- 10 agreement entered into, offered, issued or renewed by a health
- 11 <u>insurer to provide</u>, <u>deliver</u>, <u>arrange for</u>, <u>pay for or reimburse</u>
- 12 any of the costs of physical, mental or behavioral health care

<--

- 13 services. The term does not include Medicare supplement or
- 14 <u>Civilian Health and Medical Program of the Uniformed Services</u>
- 15 (CHAMPUS) supplement insurance.
- 16 * * *
- 17 ["Health insurance policy." A policy, subscriber contract,
- 18 certificate or plan that provides prescription drug coverage.
- 19 The term includes both comprehensive and limited benefit health
- 20 policies.]
- 21 * * *
- 22 "Licensee." An entity subject to oversight of the department
- 23 <u>under this act. The term includes:</u>
- 24 (1) An auditing entity.
- 25 (2) A health insurer.
- 26 (3) A pharmacy benefit manager.
- 27 * * *
- 28 <u>"Monetary advantage or penalty." An incentive or deterrent</u>
- 29 <u>imposed under a health benefit plan that affects a beneficiary's</u>
- 30 choice of pharmacy. The term includes, but is not limited to, a

- 1 <u>higher copayment, a waiver of a copayment, a reduction in</u>
- 2 reimbursement for services, a requirement or limit on the number
- 3 <u>of days of a drug supply for which reimbursement will be allowed</u>
- 4 or a promotion of one participating pharmacy over another by
- 5 these methods.
- 6 * * *
- 7 "Spread pricing." A model of prescription drug pricing in
- 8 which the PBM charges a health benefit plan or health insurer a
- 9 contracted price for prescription drugs and the contracted price
- 10 for the prescription drugs differs from the amount the PBM
- 11 directly or indirectly pays the pharmacist or pharmacy for
- 12 prescription drugs and related pharmacist services.
- 13 Section 3. Section 303 of the act is amended by adding a
- 14 subsection to read:
- 15 Section 303. Limitations.
- 16 * * *
- 17 (c) Scrivener's error.--A scrivener's error made by a
- 18 pharmacy not attributed to fraud, waste or abuse that is
- 19 discovered during an audit of the pharmacy by the PBM shall
- 20 result in the PBM recouping the dispensing fee for that
- 21 particular transaction, not the entire amount for the medication
- 22 received by the patient.
- 23 Section 4. Section 501(b)(3) of the act is amended to read:
- 24 Section 501. PBM and auditing entity registration.
- 25 * * *
- 26 (b) Term and fee.--
- 27 * * *
- 28 (3) The amount of the initial application fee and
- 29 renewal application fee shall be sufficient to fund the
- department's duties in relation to its responsibilities under

| 1 | this [chapter] \underline{ACT} but may not exceed [\$1,000] $\underline{$10,000}$. |
|----|---|
| 2 | * * * |
| 3 | Section 5. The act is amended by adding a chapter to read: |
| 4 | CHAPTER 6 |
| 5 | PHARMACY BENEFITS MANAGER CONTRACT |
| 6 | REQUIREMENTS AND PROHIBITED ACTS |
| 7 | Section 601. Contract provisions. |
| 8 | A contract between a PBM or a designee of the PBM and a |
| 9 | <pre>pharmacy may not:</pre> |
| 10 | (1) Require participation in the PBM's network |
| 11 | contingent on the pharmacy signing either an effective rate |
| 12 | contract or a contract based on the National Average Drug |
| 13 | Acquisition Cost guidelines. |
| 14 | (2) Include provisions allowing for retroactive |
| 15 | recoupment of money paid to a pharmacy by the PBM, unless |
| 16 | both parties agree to that provision. |
| 17 | (3) Base reimbursement upon general GENERIC effective < |
| 18 | rate or the brand effective rate as a condition of entering a |
| 19 | network, unless both parties agree to that provision. Any |
| 20 | additional fees must be disclosed and applied at the time of < |
| 21 | the adjudication of the claim IN WRITING 30 DAYS PRIOR TO < |
| 22 | INITIATION OF THE ADDITIONAL FEES. Fees may include: |
| 23 | (i) Transaction fees. |
| 24 | (ii) Chargebacks due to recalculation of the cost of |
| 25 | the ingredients used in a prescription drug. |
| 26 | (iii) Adjustments in the general GENERIC effective < |
| 27 | rate, brand effective rates or direct and indirect |
| 28 | remuneration fees made by the PBM. |
| 29 | Section 602. Spread pricing prohibited. |
| 30 | A health benefit plan, health insurer or PBM contracting with |

- 1 a health benefit plan or health insurer may not utilize any form
- 2 of spread pricing in this Commonwealth.
- 3 Section 603. Patient steering prohibited.
- 4 A health benefit plan, health insurer or PBM contracting with
- 5 <u>a health benefit plan or health insurer may not:</u>
- 6 (1) Require a covered individual, as a condition of
- 7 payment or reimbursement, to purchase pharmacist services,
- 8 <u>including</u>, but not limited to, prescription drugs,
- 9 exclusively through a mail-order pharmacy or PBM affiliate.
- 10 (2) Prohibit or limit any covered individual from
- 11 <u>selecting an in-network pharmacy or in-network pharmacist of</u>
- 12 <u>the covered individual's choice who meets and agrees to the</u>
- 13 <u>terms and conditions, including reimbursements, in the PBM's</u>
- 14 <u>contract.</u>
- 15 (3) Impose a monetary advantage or penalty under a
- 16 <u>health benefit plan that affects a covered individual's</u>
- 17 choice of pharmacy among those pharmacies that have chosen to
- 18 contract with the PBM under the same terms and conditions,
- including reimbursements.
- 20 (4) Use a covered individual's pharmacy services data
- 21 collected under claims processing services for the purpose of
- 22 soliciting, marketing or referring the covered individual to
- a mail-order pharmacy or PBM affiliate, except that a health
- 24 benefit plan or health insurer may use pharmacy services data
- for the purpose of administering the health benefit plan.
- 26 Section 604. Clawbacks prohibited.
- 27 (a) General rule. -- A health benefit plan, health insurer or
- 28 PBM contracting with a health benefit plan or health insurer may
- 29 not require cost-sharing in an amount or direct a pharmacy to
- 30 collect cost-sharing in an amount, greater than the lesser of

- 1 either of the following from an individual purchasing a
- 2 prescription drug:
- 3 (1) The amount an individual would pay for the
- 4 prescription drug if the prescription drug were to be
- 5 <u>purchased without coverage under a health benefit plan.</u>
- 6 (2) The net reimbursement paid to the pharmacy for the
- 7 prescription drug by the health insurer or PBM.
- 8 (b) Duty when filling a prescription. -- When filling a
- 9 prescription, if a pharmacist, pharmacy intern or technician
- 10 determines that information indicating that the cost-sharing
- 11 amount required by the patient's health benefit plan exceeds the
- 12 <u>amount that may otherwise be charged for the same prescription</u>
- 13 drug, both of the following shall apply:
- 14 (1) The pharmacist, pharmacy intern or technician shall
- 15 <u>notify the patient.</u>
- 16 (2) The patient may not be charged the higher amount.
- 17 Section 605. Network adequacy.
- 18 (a) General rule. -- A PBM shall establish a reasonably
- 19 <u>adequate and accessible PBM network for the provision of</u>
- 20 prescription drugs under a health benefit plan that shall
- 21 provide for convenient patient access to pharmacies within a
- 22 reasonable distance from a patient's residence in accordance
- 23 with the following requirements:
- 24 (1) A mail-order pharmacy shall not be included in the
- 25 calculations determining PBM network adequacy.
- 26 (2) The network may not be limited to affiliated
- 27 <u>pharmacies only.</u>
- 28 (3) The network shall meet or exceed the requirements of
- 29 42 CFR 423.120(a)(1) (relating to access to covered Part D
- 30 drugs) or successor regulation.

- 1 (b) Report requirement.--Beginning April 1, 2026, and
- 2 annually thereafter, a PBM shall file with the department a
- 3 network adequacy report describing the PBM network and the PBM
- 4 <u>network's accessibility in this Commonwealth on a form</u>
- 5 prescribed by the department, which shall be posted on the
- 6 <u>department's publicly accessible Internet website.</u>
- 7 <u>Section 606. Regulations.</u>
- 8 The department may promulgate regulations as necessary and
- 9 appropriate to carry out this chapter.
- 10 <u>Section 607. Applicability.</u>
- 11 If a contract is in effect on the effective date of this
- 12 <u>section that conflicts with this chapter, the provision of this</u>
- 13 chapter shall not apply until the date the contract is amended,
- 14 <u>extended or renewed.</u>
- 15 Section 6. The act is amended by adding a section to read:
- 16 <u>Section 703.1. Transparency report required.</u>
- 17 (a) General rule.--Beginning July 1, 2026, and annually
- 18 thereafter, each licensed PBM shall submit a transparency report
- 19 containing data from the prior calendar year to the department.
- 20 The transparency report shall contain the following information:
- 21 (1) The aggregate amount of all rebates that the PBM
- 22 received from all pharmaceutical manufacturers for all health
- 23 <u>benefit plan and health insurer clients and for each health</u>
- benefit plan or health insurer client.
- 25 (2) The aggregate administrative fees that the PBM
- received from all manufacturers for all health benefit plan
- 27 <u>and health insurer clients and for each health benefit plan</u>
- 28 or health insurer client.
- 29 (3) The aggregate retained rebates that the PBM received
- from all pharmaceutical manufacturers and did not pass

- 1 through to health benefit plan or health insurer clients.
- 2 (4) The highest, lowest and mean aggregate retained
- 3 rebate percentage for all health benefit plan or health
- 4 <u>insurer clients and for each health benefit plan or health</u>
- 5 insurer client.
- 6 (5) For a PBM that controls or is affiliated with a
- 7 pharmacy, a description of any differences between what the
- 8 PBM reimburses or charges affiliated and nonaffiliated
- 9 <u>pharmacies.</u>
- 10 (b) Publication. -- Within 60 days of receipt, the department
- 11 shall publish the transparency report under this section on the
- 12 <u>department's publicly accessible Internet website in a form that</u>
- 13 does not disclose the identity of a specific health benefit plan
- 14 or health insurer, the prices charged for specific drugs or
- 15 classes of drugs or the amount of any rebates provided for
- 16 specific drugs or classes of drugs.
- 17 (c) Additional categories. -- The department may, by
- 18 regulation, direct PBMs to include additional categories for
- 19 <u>aggregated data from health benefit plan or health insurer</u>
- 20 clients in the annual transparency report submitted under this
- 21 section.
- 22 Section 7. Section 901 of the act is amended to read:
- 23 Section 901. Scope of enforcement authority.
- 24 (a) Scope. -- The department may investigate and enforce the
- 25 provisions of this act only insofar as the actions or inactions
- 26 being investigated relate to prescription drug coverage under a
- 27 health [insurance policy] benefit plan.
- [(b) Remedy.--Actions or inactions within the scope of the
- 29 department's investigative and enforcement authority under
- 30 subsection (a) found to violate this act constitute "unfair

- 1 methods of competition" and "unfair or deceptive acts or
- 2 practices" within the meaning of section 5 of the act of July
- 3 22, 1974 (P.L.589, No.205), known as the Unfair Insurance
- 4 Practices Act. A proceeding under this section shall be
- 5 conducted in accordance with 2 Pa.C.S. Ch. 5 Subch. A (relating
- 6 to practice and procedure of Commonwealth agencies).]
- 7 (b.1) Examination and access to records.--
- 8 (1) The department may order a PBM, a health insurer and
- 9 <u>a PBM's or health insurer's affiliates to produce records</u>,
- 10 books or other information as reasonably necessary to
- 11 <u>ascertain compliance with this act.</u>
- 12 (2) The department may examine or audit the books and
- 13 records of a PBM, a health insurer and a PBM's or health
- insurer's affiliates to ascertain compliance with this act.
- 15 The examination shall be conducted in accordance with Article
- 16 IX of the act of May 17, 1921 (P.L.789, No.285), known as the
- 17 Insurance Department Act of 1921.
- 18 (c) Penalties.--Upon the determination, after notice and
- 19 hearing, that this act has been violated, the commissioner may
- 20 impose the following penalties:
- 21 (1) Suspension or revocation of the licensee's license,
- 22 <u>authorization to operate or registration.</u>
- 23 (2) Refusal to issue or renew a license, authorization
- 24 <u>to operate or registration.</u>
- 25 (3) A cease and desist order.
- 26 (4) Order reimbursement to an insured, pharmacy or
- 27 <u>dispenser that has incurred a monetary loss as a result of a</u>
- 28 violation of this act.
- 29 (5) For each violation of this act that a licensee knew
- or reasonably should have known was a violation, a penalty of

- 1 <u>not more than \$100,000, not to exceed an aggregate penalty of</u>
- 2 \$1,000,000 in a single calendar year.
- 3 (6) For each violation of this act that a licensee did
- 4 <u>not know nor reasonably should have known was a violation, a</u>
- 5 penalty of not more than \$50,000, not to exceed an aggregate
- 6 penalty of \$500,000 in a single calendar year.
- 7 Section 8. The act is amended by adding sections to read:
- 8 <u>Section 902. Regulations.</u>
- 9 The department may promulgate regulations as necessary and
- 10 appropriate to carry out this chapter.
- 11 <u>Section 903. Construction.</u>
- 12 Nothing in this act shall be construed to apply to the
- 13 conduct of a PBM in connection with a contract with a self-
- 14 <u>funded group health plan subject to 29 U.S.C. Ch. 18 (relating</u>

<--

- 15 to Employee Retirement Income Security Program) OR EXEMPTED
- 16 FROM 29 U.S.C. CH. 18 SUBCH. I (RELATING TO PROTECTION OF
- 17 EMPLOYEE BENEFIT RIGHTS) BY 29 U.S.C. § 1003(B) (RELATING TO
- 18 <u>COVERAGE</u>).
- 19 Section 9. This act shall take effect in 60 days.